Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aridis Pharmaceuticals, Inc. ARDS
$0.22
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
7785525.00000000
-
week52high
2.77
-
week52low
0.15
-
Revenue
1535000
-
P/E TTM
0
-
Beta
0.99414600
-
EPS
-1.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Hold | Buy | 16 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 июл 2021 г. |
| H.C. Wainwright | Buy | 15 мая 2020 г. | |
| Roth Capital | Buy | 19 февр 2020 г. | |
| H.C. Wainwright | Buy | 30 дек 2019 г. | |
| HC Wainwright & Co. | Buy | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RUFFOLO ROBERT R | A | 10000 | 10000 | 05 дек 2022 г. |
| Patzer Eric | A | 24000 | 24000 | 05 дек 2022 г. |
| Truong Vu | A | 30000 | 30000 | 05 дек 2022 г. |
| HAMILTON JOHN F | A | 10000 | 10000 | 05 дек 2022 г. |
| KURLAND FRED | A | 8000 | 8000 | 05 дек 2022 г. |
| Gibbs Craig S | A | 10000 | 10000 | 05 дек 2022 г. |
| Jafri Hasan | A | 20000 | 20000 | 05 дек 2022 г. |
| Windham-Bannister Susan Richards | A | 10000 | 10000 | 05 дек 2022 г. |
| Truong Vu | A | 687750 | 88360 | 07 июн 2022 г. |
| HAMILTON JOHN F | A | 61540 | 9400 | 04 окт 2021 г. |
Новостная лента
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
Zacks Investment Research
14 мар 2023 г. в 13:44
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
21 ноя 2022 г. в 21:04
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
16 авг 2022 г. в 18:48
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?